评估 DPP4 和 SGLT2 抑制剂联合疗法对 2 型糖尿病患者的代谢和身体影响:一项观察性前瞻性试点研究。

IF 1.5 Q2 MEDICINE, GENERAL & INTERNAL
JMA journal Pub Date : 2024-07-16 Epub Date: 2024-06-10 DOI:10.31662/jmaj.2023-0214
Ayako Nagayama, Tetsuaki Inokuchi, Kenji Ashida, Chizuko Inada, Tomoki Homma, Hiroshi Miyazaki, Takeki Adachi, Shimpei Iwata, Seiichi Motomura, Masatoshi Nomura
{"title":"评估 DPP4 和 SGLT2 抑制剂联合疗法对 2 型糖尿病患者的代谢和身体影响:一项观察性前瞻性试点研究。","authors":"Ayako Nagayama, Tetsuaki Inokuchi, Kenji Ashida, Chizuko Inada, Tomoki Homma, Hiroshi Miyazaki, Takeki Adachi, Shimpei Iwata, Seiichi Motomura, Masatoshi Nomura","doi":"10.31662/jmaj.2023-0214","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to assess the efficacy of combined administration of dipeptidyl peptide-4 (DPP4) and sodium-glucose cotransporter-2 (SGLT2) inhibitors on metabolic disorders and their preferable and complementary effects.</p><p><strong>Methods: </strong>The effectiveness of a 24-week intervention on metabolic parameters (including glucose profile), physical functions (grip strength and calf circumference), and health-related quality of life (HR-QOL) was analyzed using the International Physical Activity Questionnaire and Geriatric Depression Scale 5. A total of 39 patients with type-2 diabetes mellitus (T2DM) treated with the combination of DPP4 and SGLT2 inhibitors were included in this multicenter pilot study.</p><p><strong>Results: </strong>Combination therapy significantly reduced the HbA1c level (median [interquartile range]) after 24 weeks (pretreatment: 7.7% [7.3-8.2] vs. posttreatment: 7.1% [6.6-7.9], <i>P</i> < 0.001). The grip strength significantly increased after 24 weeks (1.7 ± 2.7 kg, <i>P</i> < 0.001), while the mean calf circumference and body mass index significantly decreased. In particular, administration of the SGLT2 inhibitor significantly increased total physical activity in participants aged ≥65 years (<i>P</i> = 0.003), while psychological QOL did not significantly improve.</p><p><strong>Conclusions: </strong>Combination therapy with DPP4 and SGLT2 inhibitors decreased HbA1c levels and improved physical function in patients with T2DM. This study confirmed the effectiveness of combination therapy for metabolic disorders and suggested its beneficial and complementary effects. Therefore, advances in treatment plans to achieve further improvements in glucose profiles using DPP4 and SGLT2 inhibitors are recommended to enhance the QOL of patients with T2DM. Clinical trial number: University Hospital Medical Information Network Center: UMIN000045375.</p>","PeriodicalId":73550,"journal":{"name":"JMA journal","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301034/pdf/","citationCount":"0","resultStr":"{\"title\":\"Assessing the Metabolic and Physical Effects of Combined DPP4 and SGLT2 Inhibitor Therapy in Patients with Type-2 Diabetes Mellitus: An Observational Prospective Pilot Study.\",\"authors\":\"Ayako Nagayama, Tetsuaki Inokuchi, Kenji Ashida, Chizuko Inada, Tomoki Homma, Hiroshi Miyazaki, Takeki Adachi, Shimpei Iwata, Seiichi Motomura, Masatoshi Nomura\",\"doi\":\"10.31662/jmaj.2023-0214\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>This study aimed to assess the efficacy of combined administration of dipeptidyl peptide-4 (DPP4) and sodium-glucose cotransporter-2 (SGLT2) inhibitors on metabolic disorders and their preferable and complementary effects.</p><p><strong>Methods: </strong>The effectiveness of a 24-week intervention on metabolic parameters (including glucose profile), physical functions (grip strength and calf circumference), and health-related quality of life (HR-QOL) was analyzed using the International Physical Activity Questionnaire and Geriatric Depression Scale 5. A total of 39 patients with type-2 diabetes mellitus (T2DM) treated with the combination of DPP4 and SGLT2 inhibitors were included in this multicenter pilot study.</p><p><strong>Results: </strong>Combination therapy significantly reduced the HbA1c level (median [interquartile range]) after 24 weeks (pretreatment: 7.7% [7.3-8.2] vs. posttreatment: 7.1% [6.6-7.9], <i>P</i> < 0.001). The grip strength significantly increased after 24 weeks (1.7 ± 2.7 kg, <i>P</i> < 0.001), while the mean calf circumference and body mass index significantly decreased. In particular, administration of the SGLT2 inhibitor significantly increased total physical activity in participants aged ≥65 years (<i>P</i> = 0.003), while psychological QOL did not significantly improve.</p><p><strong>Conclusions: </strong>Combination therapy with DPP4 and SGLT2 inhibitors decreased HbA1c levels and improved physical function in patients with T2DM. This study confirmed the effectiveness of combination therapy for metabolic disorders and suggested its beneficial and complementary effects. Therefore, advances in treatment plans to achieve further improvements in glucose profiles using DPP4 and SGLT2 inhibitors are recommended to enhance the QOL of patients with T2DM. Clinical trial number: University Hospital Medical Information Network Center: UMIN000045375.</p>\",\"PeriodicalId\":73550,\"journal\":{\"name\":\"JMA journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301034/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JMA journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31662/jmaj.2023-0214\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMA journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31662/jmaj.2023-0214","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

简介本研究旨在评估联合使用二肽肽-4(DPP4)和钠-葡萄糖共转运体-2(SGLT2)抑制剂对代谢紊乱的疗效及其优劣互补作用:使用国际体力活动问卷和老年抑郁量表 5 分析了为期 24 周的干预对代谢参数(包括血糖谱)、身体功能(握力和小腿围)和健康相关生活质量(HR-QOL)的影响。这项多中心试点研究共纳入了39名接受DPP4和SGLT2抑制剂联合治疗的2型糖尿病(T2DM)患者:24周后,联合疗法明显降低了HbA1c水平(中位数[四分位数间距])(治疗前:7.7% [7.3-8.2] vs. 治疗后:7.1% [6.6-7.9],P < 0.001)。24 周后,握力明显增加(1.7 ± 2.7 千克,P < 0.001),而平均小腿围和体重指数明显下降。特别是,服用 SGLT2 抑制剂后,年龄≥65 岁的参与者的总体力活动量明显增加(P = 0.003),而心理 QOL 没有明显改善:结论:DPP4 和 SGLT2 抑制剂联合治疗可降低 T2DM 患者的 HbA1c 水平并改善其身体功能。这项研究证实了联合疗法对代谢紊乱的有效性,并提出了其有益的互补作用。因此,建议改进治疗方案,使用 DPP4 和 SGLT2 抑制剂进一步改善血糖状况,以提高 T2DM 患者的 QOL。临床试验编号大学医院医学信息网络中心:UMIN000045375。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Assessing the Metabolic and Physical Effects of Combined DPP4 and SGLT2 Inhibitor Therapy in Patients with Type-2 Diabetes Mellitus: An Observational Prospective Pilot Study.

Introduction: This study aimed to assess the efficacy of combined administration of dipeptidyl peptide-4 (DPP4) and sodium-glucose cotransporter-2 (SGLT2) inhibitors on metabolic disorders and their preferable and complementary effects.

Methods: The effectiveness of a 24-week intervention on metabolic parameters (including glucose profile), physical functions (grip strength and calf circumference), and health-related quality of life (HR-QOL) was analyzed using the International Physical Activity Questionnaire and Geriatric Depression Scale 5. A total of 39 patients with type-2 diabetes mellitus (T2DM) treated with the combination of DPP4 and SGLT2 inhibitors were included in this multicenter pilot study.

Results: Combination therapy significantly reduced the HbA1c level (median [interquartile range]) after 24 weeks (pretreatment: 7.7% [7.3-8.2] vs. posttreatment: 7.1% [6.6-7.9], P < 0.001). The grip strength significantly increased after 24 weeks (1.7 ± 2.7 kg, P < 0.001), while the mean calf circumference and body mass index significantly decreased. In particular, administration of the SGLT2 inhibitor significantly increased total physical activity in participants aged ≥65 years (P = 0.003), while psychological QOL did not significantly improve.

Conclusions: Combination therapy with DPP4 and SGLT2 inhibitors decreased HbA1c levels and improved physical function in patients with T2DM. This study confirmed the effectiveness of combination therapy for metabolic disorders and suggested its beneficial and complementary effects. Therefore, advances in treatment plans to achieve further improvements in glucose profiles using DPP4 and SGLT2 inhibitors are recommended to enhance the QOL of patients with T2DM. Clinical trial number: University Hospital Medical Information Network Center: UMIN000045375.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信